Two‐year outcomes between ST‐elevation and non‐ST‐elevation myocardial infarction in patients with chronic kidney disease undergoing newer‐generation drug‐eluting stent implantation

2021 ◽  
Author(s):  
Yong Hoon Kim ◽  
Ae‐Young Her ◽  
Myung Ho Jeong ◽  
Byeong‐Keuk Kim ◽  
Sung‐Jin Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Stent Implantation ◽  
St Elevation Myocardial Infarction ◽  
Drug Eluting Stent ◽  
Drug Eluting ◽  
St Elevation

scholarly journals Outcomes of Different Reperfusion Strategies of Multivessel Disease Undergoing Newer-Generation Drug-Eluting Stent Implantation in Patients with Non-ST-Elevation Myocardial Infarction and Chronic Kidney Disease

2021 ◽  
Vol 10 (20) ◽  
pp. 4629
Author(s):  
Yong Hoon Kim ◽  
Ae-Young Her ◽  
Myung Ho Jeong ◽  
Byeong-Keuk Kim ◽  
Sung-Jin Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Stent Implantation ◽  
Multivessel Disease ◽  
St Elevation Myocardial Infarction ◽  
Secondary Outcome ◽  
Drug Eluting Stent ◽  
Drug Eluting ◽  
St Elevation

Because available data are limited, we compared the 2-year clinical outcomes among different reperfusion strategies (culprit-only percutaneous coronary intervention (C-PCI), multivessel PCI (M-PCI), complete revascularization (CR) and incomplete revascularization (IR)) of multivessel disease (MVD) undergoing newer-generation drug-eluting stent implantation in patients with non-ST-elevation myocardial infarction (NSTEMI) and chronic kidney disease (CKD). In this nonrandomized, multicenter, retrospective cohort study, a total of 1042 patients (C-PCI, n = 470; M-PCI, n = 572; CR, n = 432; IR, n = 140) were recruited from the Korea Acute Myocardial Infarction Registry (KAMIR) and evaluated. The primary outcome was the occurrence of major adverse cardiac events, defined as all-cause death, recurrent myocardial infarction and any repeat coronary revascularization. The secondary outcome was probable or definite stent thrombosis. During the 2-year follow-up period, the cumulative incidences of the primary (C-PCI vs. M-PCI, adjusted hazard ratio (aHR), 1.020; p = 0.924; CR vs. IR, aHR, 1.012; p = 0.967; C-PCI vs. CR, aHR, 1.042; p = 0.863; or C-PCI vs. IR, aHR, 1.060; p = 0.844) and secondary outcomes were statistically insignificant in the four comparison groups. In the contemporary newer-generation DES era, C-PCI may be a better reperfusion option for patients with NSTEMI with MVD and CKD rather than M-PCI, including CR and IR, with regard to the procedure time and the risk of contrast-induced nephropathy. However, further well-designed, large-scale randomized studies are warranted to confirm these results.

scholarly journals Severe thrombocytopenia soon after drug-eluting stent implantation in ST-elevation myocardial infarction

2015 ◽  
Vol 4 ◽  
pp. 354-356
Author(s):  
Agnieszka Łebek-Szatańska ◽  
Anna Pośnik-Kisło ◽  
Wiesława Błaszak-Ciećwierska ◽  
Marek Dąbrowski
Keyword(s):  
Myocardial Infarction ◽  
Stent Implantation ◽  
St Elevation Myocardial Infarction ◽  
Drug Eluting Stent ◽  
Severe Thrombocytopenia ◽  
Drug Eluting ◽  
St Elevation

Risk of heart failure following drug-eluting stent implantation in patients with non–ST–elevation myocardial infarction

2021 ◽  
Vol 316 ◽  
pp. 84-89
Author(s):  
Chao-Feng Lin ◽  
Ya-Hui Chang ◽  
Fa-Chang Yu ◽  
Chen-Ting Tsai ◽  
Chun-Chao Chen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Stent Implantation ◽  
St Elevation Myocardial Infarction ◽  
Drug Eluting Stent ◽  
Drug Eluting ◽  
St Elevation
Sign in / Sign up

Export Citation Format

Share Document